A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.
Inclusion Criteria:
Exclusion Criteria:
Patients presenting with any of the following:
Boyton Beach, Florida 33435, United States
Fort Meyers, Florida 33966, United States
Kauno M. Sav, LT-47144, Lithuania
Burcharest, 020125, Romania
KwaZulu-Natal, Ladysmieth 3370, South Africa
Western Cape, Paarl 7646, South Africa
Gauteng, Pretoria 0001, South Africa
Gauteng, Soweto 2013, South Africa
Jung Gu, Daegu 700-721, South Korea
Kangwon-do, 220-71, South Korea
Tainan, Fukien 70403, Taiwan
Taipai, Taiwan
Yung Kang City, 71044, Taiwan
Zaporizhia, 69032, Ukraine